10 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 10 of 10 clinical reviews.
Alendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Review the clinical trial data, ACR guideline recommendations, dosing, risks, and how it compares to on-label alternatives like risedronate and denosumab.
Alendronate (Fosamax) is FDA-approved for glucocorticoid-induced osteoporosis. Review the clinical trial data, ACR guideline recommendations, dosing, and how it compares to other GIO treatments.
Alendronate (Fosamax) is used off-label for glucocorticoid-induced osteoporosis. Review the dosing protocol, clinical trial evidence, guideline recommendations, and how it compares to FDA-approved alternatives.
Alendronate (Fosamax) is FDA-approved for male osteoporosis at 10 mg daily or 70 mg weekly. Learn the dosing protocol, key trial data, monitoring plan, and how it compares to other options for men.
A detailed evidence review of alendronate (Fosamax) for male osteoporosis, covering FDA approval status, key trial data, dosing, BMD outcomes, and fracture risk reduction in men.
Alendronate (Fosamax) is FDA-approved for osteoporosis in postmenopausal women but used off-label in men. Review the clinical trial evidence, dosing, risks, and when a physician might prescribe it for male bone loss.
Alendronate (Fosamax) is FDA-approved for male osteoporosis at 10 mg/day or 70 mg/week. This guide covers the evidence base, off-label nuances, dosing, and monitoring requirements for men on bisphosphonate therapy.
Alendronate (Fosamax) is FDA-approved for Paget's disease at 40 mg daily for 6 months. Learn the full dosing protocol, monitoring targets, retreatment criteria, and how it compares to zoledronic acid and risedronate.
Alendronate (Fosamax) is FDA-approved for Paget's disease of bone. This evidence summary covers dosing, trial data, guideline recommendations, and how it compares to other bisphosphonates for Paget's.
Alendronate (Fosamax) is used off-label for Paget's disease of bone. Review the clinical evidence, FDA-approved alternatives, dosing protocols, risks, and when clinicians choose this bisphosphonate over other options.